Key Points
- Director Bruce Booth executed multiple sales, including 4,159 shares on April 14 at an average $89.97 under a pre-arranged Rule 10b5-1 plan, and previously sold 81,866 shares on March 2 for about $7.38M, substantially reducing his stake.
- Kymera missed quarterly expectations, reporting EPS of -$0.97 (vs. -$0.77 est.) and revenue of $2.87M (down 60.8% year‑over‑year); the stock is down ~3.2%, trading within a 52‑week range of $24.72–$103.00 and carrying a market cap of $7.03B.
- Analysts remain mostly bullish with a consensus rating of "Moderate Buy" and an average price target of $118.90, with several firms recently lifting targets into the $110–$128 range.
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) COO Jeremy Chadwick sold 1,300 shares of the business's stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $90.00, for a total value of $117,000.00. Following the sale, the chief operating officer owned 61,202 shares of the company's stock, valued at approximately $5,508,180. This represents a 2.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Kymera Therapeutics Stock Down 3.2%
Shares of NASDAQ:KYMR opened at $86.14 on Friday. Kymera Therapeutics, Inc. has a 12-month low of $24.72 and a 12-month high of $103.00. The stock has a market cap of $7.03 billion, a PE ratio of -23.41 and a beta of 2.28. The business has a 50 day moving average of $83.89 and a 200-day moving average of $74.23.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The firm had revenue of $2.87 million for the quarter, compared to the consensus estimate of $14.80 million. During the same quarter in the prior year, the firm earned ($0.88) EPS. The company's revenue was down 60.8% on a year-over-year basis. Equities research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.
Key Stories Impacting Kymera Therapeutics
Here are the key news stories impacting Kymera Therapeutics this week:
- Neutral Sentiment: Director Bruce Booth executed multiple small sales over April 14–15 under a pre-arranged Rule 10b5-1 plan (3,135 @ ~$90.10; 2,200 @ ~$89.95; 4,159 @ ~$89.97). Because these were part of a 10b5-1 plan, they are largely viewed as planned/liquidity-driven rather than a signal of private negative information. SEC Form 4
- Negative Sentiment: COO Jeremy G. Chadwick sold 6,551 shares across April 14–15 (~$90 avg), representing roughly a 7.9% then 2.1% reduction in his reported holdings; these trades were disclosed without a 10b5-1 designation, which can attract greater investor concern about insider confidence. SEC Form 4
- Negative Sentiment: Insider Noah Goodman sold 1,347 shares on April 14 at about $90/share; that trade was also disclosed without a stated 10b5-1 plan and reduces insider ownership modestly. SEC Form 4
Institutional Investors Weigh In On Kymera Therapeutics
Institutional investors have recently made changes to their positions in the stock. Smartleaf Asset Management LLC boosted its stake in shares of Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock valued at $42,000 after buying an additional 424 shares during the period. Larson Financial Group LLC lifted its stake in Kymera Therapeutics by 81.5% during the third quarter. Larson Financial Group LLC now owns 777 shares of the company's stock worth $44,000 after purchasing an additional 349 shares during the last quarter. Osaic Holdings Inc. lifted its stake in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company's stock worth $48,000 after purchasing an additional 1,083 shares during the last quarter. Bessemer Group Inc. lifted its stake in Kymera Therapeutics by 652.0% during the third quarter. Bessemer Group Inc. now owns 940 shares of the company's stock worth $53,000 after purchasing an additional 815 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Kymera Therapeutics during the fourth quarter worth $63,000.
Analyst Ratings Changes
Several equities research analysts recently issued reports on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Kymera Therapeutics in a research note on Thursday, January 22nd. Piper Sandler boosted their price target on Kymera Therapeutics from $125.00 to $140.00 and gave the company an "overweight" rating in a research note on Thursday, February 26th. Morgan Stanley reiterated an "overweight" rating and issued a $123.00 price target on shares of Kymera Therapeutics in a research note on Thursday, February 26th. Stephens boosted their price target on Kymera Therapeutics from $95.00 to $100.00 and gave the company an "overweight" rating in a research note on Monday, March 2nd. Finally, BTIG Research cut their price target on Kymera Therapeutics from $138.00 to $134.00 and set a "buy" rating for the company in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $118.90.
View Our Latest Stock Report on KYMR
Kymera Therapeutics Company Profile
(
Get Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
